文献速递腹部MR

非高危人群肝血管平滑肌脂肪瘤与肝细胞癌的MRI鉴别评分

Differentiation between hepatic angiomyolipoma and hepatocellular carcinoma in individuals who are not at-risk for hepatocellular carcinoma.
PubMed 文献 · Eur J Radiol · 2023-07-06

本研究基于钆塞酸增强MRI开发并验证了AML-HCC评分,用于鉴别非肝细胞癌高危个体的肝血管平滑肌脂肪瘤与肝细胞癌。评分包含女性、早期引流静脉、T2均匀性、坏死或严重缺血及肝胆期信号高于脾脏五项,在训练队列敏感度80%、特异度95%,验证队列分别为100%和80%。

要点

  • 非高危人群肝脏富血供病变需鉴别AML与HCC,可用AML-HCC评分辅助。
  • 评分≥1时提示HCC可能大,训练队列特异度95%,验证队列敏感度100%。
  • 早期引流静脉(+2分)和女性(+1分)提示HCC,坏死或严重缺血(-2分)提示AML。

关键影像表现/征象

  • 评分中女性计1分,早期引流静脉计2分,T2均匀性计1分,坏死或严重缺血计-2分,肝胆期信号高于脾脏计-1分。

诊断标准与关键数值

  • AML-HCC评分≥1分时,训练队列鉴别AML与HCC的敏感度80%、特异度95%,验证队列敏感度100%、特异度80%。

临床应用与阅片要点

  • 对非高危人群的肝脏富血供病变,可结合女性、早期引流静脉、T2均匀性、坏死或严重缺血及肝胆期信号高于脾脏等征象计算评分辅助鉴别。

局限性

  • 本研究为回顾性设计,验证队列AML病例仅4例,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To develop a practical methodfor differentiating hepatocellular carcinoma (HCC) from angiomyolipoma (AML) in individuals who are not at-risk for HCC.

METHOD: We retrospectively enrolled consecutive patients who underwent gadoxetic acid-enhanced liver magnetic resonance imaging (MRI) and pathological confirmation between January 2008 and April 2022. Patients who underwent prior treatment, those with multiple lesions, or those at-risk for HCC were excluded. The training cohort included patients with pathological confirmation between 2008 and 2019, whereas the validation cohort included the remaining cases. Independent reviews of the MRI were performed by two reviewers. Using the clinical and MRI findings, we developed AML-HCC score using Firth's logistic regression in the training cohort, and the diagnostic performance was validated in the validation cohort.

RESULTS: Of the 206 patients, 156 were assigned to the training cohort (25 and 131 patients with AML and HCC, respectively) and 50 were assigned to the validation cohort (4 and 46 patients with AML and HCC, respectively). The AML-HCC score was defined as the sum of female (score 1), early draining vein (score 2), T2 homogeneity (score 1), necrosis or severe ischaemia (score -2), and HBP hyperintensity to spleen (score -1). When the AML-HCC score was ≥1, the sensitivity and specificity were 80% and 95% for the training cohort and 100% and 80% for the validation cohort, respectively.

CONCLUSIONS: We developed and validated an AML-HCC score to differentiate between AML and HCC in individuals who are not at-risk for HCC, and our model demonstrated good diagnostic performance.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Park S, Kim MJ, Han K, et al. Differentiation between hepatic angiomyolipoma and hepatocellular carcinoma in individuals who are not at-risk for hepatocellular carcinoma. Eur J Radiol. 2023. PMID: 37451136. doi:10.1016/j.ejrad.2023.110957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。